Deoxyribonucleoside triphosphate metabolism and the mammalian cell cycle. Effects of hydroxyurea on mutant and wild-type mouse S49 T-lymphoma cells.
DNA precursor synthesis can be blocked specifically by the drug hydroxyurea (HU) which has therefore been used for anticancer therapy. High concentrations of HU, however, affect other processes than DNA synthesis; nevertheless, most studies on the biological action of HU have been made with concentrations at least one order of magnitude higher than those needed for cell-growth inhibition. In this study we characterized the effects of low concentrations of HU (i.e. concentrations leading to 50% inhibition of cell growth in 72 h) on cell cycle kinetics and nucleotide pools in mouse S49 cells with various defined alterations in DNA precursor synthesis. The effect of 50 microM HU on deoxyribonucleoside triphosphate pools was a 2-3-fold decrease in the dATP and dGTP pools, with no change in the dCTP pool and a certain increase in the dTTP pool. Addition of deoxycytidine or thymidine led to a partial reversal of the growth inhibition and cell-cycle perturbation caused by HU, and was accompanied by an increased level of the deoxyribonucleoside triphosphates. Addition of purine deoxyribonucleoside gave no protection, indicating that salvage of these nucleosides could not supply precursors for DNA synthesis in T-lymphoma cells. We observed a higher sensitivity to HU of cells lacking purine nucleoside phosphorylase or with a ribonucleotide reductase with altered allosteric regulation. Cells lacking thymidine kinase or deoxycytidine kinase were just as sensitive as wild-type cells.
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects*; D002460:Cell Line; D003838:Deoxyadenine Nucleotides / Q000378:metabolism; D003842:Deoxycytidine Kinase / Q000235:genetics / Q000502:physiology; D003845:Deoxycytosine Nucleotides / Q000378:metabolism; D003848:Deoxyguanine Nucleotides / Q000378:metabolism; D003854:Deoxyribonucleotides / Q000378:metabolism*; D006918:Hydroxyurea / Q000494:pharmacology*; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D009154:Mutation; D011683:Purine-Nucleoside Phosphorylase / Q000235:genetics / Q000502:physiology; D012264:Ribonucleotide Reductases / Q000235:genetics / Q000502:physiology; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D013937:Thymidine Kinase / Q000235:genetics / Q000502:physiology; D013942:Thymine Nucleotides / Q000378:metabolism
D003838:Deoxyadenine Nucleotides; D003845:Deoxycytosine Nucleotides; D003848:Deoxyguanine Nucleotides; D003854:Deoxyribonucleotides; D013942:Thymine Nucleotides; C024107:2'-deoxycytidine 5'-triphosphate; C029603:deoxyguanosine triphosphate; D012264:Ribonucleotide Reductases; D011683:Purine-Nucleoside Phosphorylase; D013937:Thymidine Kinase; D003842:Deoxycytidine Kinase; C026600:2'-deoxyadenosine triphosphate; C024157:thymidine 5'-triphosphate; D006918:Hydroxyurea